In these regards, GLP-1 agonist has demonstrated significant weight reduction benefits [12], a double-blinded trial conducted on participants with BMI of 30 or more without T2DM or BMI of 27 or more with treated or untreated dyslipidemia or hypertension showed that 63.2% of patients in the GLP agonist group lost at least 5% of their body weight compared to the 27.1% in the placebo group [12]. This evidence concerns the gene GLP1R and metabolic syndrome.